Background {#section5-2042018820938240}
==========

Mitochondrial disease is a term used to describe a set of heterogeneous genetic diseases caused by impaired structure or function of mitochondria encoded by nuclear DNA and mitochondrial DNA (mtDNA).^[@bibr1-2042018820938240]^ As vital organelles in cells, mitochondria participate in cell metabolism, including the tricarboxylic acid (TCA) cycle, gluconeogenesis, oxidative phosphorylation, fatty acid oxidation, urea cycle, and ketogenesis.^[@bibr2-2042018820938240]^ Most importantly, mitochondria as cell energy units produce 95% of ATP in order to meet cell energy requirements by the oxidative phosphorylation (OXPHOS) system. Therefore, mitochondrial disease often affects multiple systems, notably energy-consuming tissues or organs, such as brain, nerves, muscles, and heart.^[@bibr3-2042018820938240]^ The clinical manifestations also range from asymptomatic manifestation to severe multiple organ injury, including central neurological features (including stroke-like episodes, encephalopathy, ataxia, seizures, and dementia), and peripheral neurological features (including peripheral neuropathy, myopathy, and ophthalmoplegia). The age of onset ranges from the neonatal period to adulthood. The complexity of mitochondrial disease not only seriously affects patients' quality of life, but also increases the financial burden on patients' families. It also presents some difficulties to the scientific research of mitochondrial diseases. At present, there are no authoritative epidemiological data in the world. The estimated prevalence of mitochondrial diseases is 1/8500--1/4300,^[@bibr4-2042018820938240],[@bibr5-2042018820938240]^ in which the prevalence of adults ranges from 6.9/100,000 to 12.5/100,000,^[@bibr5-2042018820938240],[@bibr6-2042018820938240]^ and the one of children is 4.7--15/100,000.^[@bibr3-2042018820938240],[@bibr7-2042018820938240][@bibr8-2042018820938240][@bibr9-2042018820938240][@bibr10-2042018820938240][@bibr11-2042018820938240]--[@bibr12-2042018820938240]^ The incidence may be higher in areas with similar consanguinity of specific pathogenetic genes.^[@bibr3-2042018820938240]^

Currently, remarkable progress has been reported with regard to the mechanism and classification of mitochondrial disease, although no authoritative treatment has been recommended worldwide. Most studies have reported symptomatic and supportive treatment, including medication, diet therapy, and exercise therapy. In the field of medication, several drugs have been reported to enhance the function of mitochondria: antioxidants (coenzyme Q10 and vitamin C), respiratory chain auxiliary factors (nicotine, riboflavin, and coenzyme Q10), improvement of muscle lactic acid poisoning (dichloroacetate), and supplementation of deficient substances (creatine, levocarnitine).^[@bibr13-2042018820938240]^ However, the effectiveness of these drugs has not been determined. The Consensus on Diagnosis and Treatment of the Mitochondrial Medicine Society states that case reports, a limited number of case series, and small open-labeled studies are the main supporting evidence for the treatment of mitochondrial disease.^[@bibr14-2042018820938240],[@bibr15-2042018820938240]^ In addition, dichloroacetate was reported to cause toxic neuropathy in MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes) in a randomized controlled trial,^[@bibr16-2042018820938240]^ although it was effective for lactic acidosis. Therefore, medical treatments for mitochondrial disease are in urgent need of new discovery.

As an endogenous substance, pyruvate plays a crucial role in the metabolism of three principal substances, and is located at a metabolic branch point between glycolysis and mitochondrial oxidation. It is well known that pyruvate is synthesized mainly as the end product of glycolysis in the cytoplasm under normal physiological circumstances. In addition, pyruvate is also generated by amino acids (such as alanine, cysteine, serine, and glycine), malate, and lactate. In the cytoplasm, pyruvate can either be consumed as an amine receptor for alanine transaminase (ALT), metabolized to lactate and NAD+ by lactate dehydrogenase (LDH) to produce a few ATP for cells under hypoxic conditions, and excreted from the cell *via* the monocarboxylate transporter (MCT). Pyruvate can also enter into the mitochondrial matrix *via* the mitochondrial pyruvate carrier (MPC) and be converted to acetyl-CoA by pyruvate dehydrogenase complex (PDHC).^[@bibr17-2042018820938240]^ Subsequently, acetyl-CoA can combine with oxaloacetate to form citrate and begin the TCA cycle to yield ATP, NADH, and FADH~2~, and the latter two molecules can transfer their energy to the electron transport chain.^[@bibr17-2042018820938240]^ Alternatively, pyruvate may be transformed into oxaloacetate by pyruvate carboxylase (PC) in the mitochondria, which is an essential step in gluconeogenesis. Therefore, pyruvate play a central role in cellular homeostasis ([Figure 1](#fig1-2042018820938240){ref-type="fig"}).

![Pyruvate metabolic pathways and the potential mechanism for treating mitochondrial diseases: pyruvate is derived from glycolysis, amino acids (such as alanine, cysteine, serine, and glycine), malate, and lactate under different situations. In the cytoplasm, pyruvate can be transformed into alanine, metabolized to lactate and NAD+ by LDH, and excreted from the cell *via* MCT. Pyruvate can also enter into the mitochondria *via* MPC and convert to acetyl-CoA by PDHC. Subsequently, acetyl-CoA can combine with oxaloacetate to form citrate and begin the TCA cycle to yield ATP, NADH and FADH~2~, and the latter two molecules can transfer their energy to the electron transport chain. In other situations, pyruvate may be consumed by PC to generate oxaloacetate for gluconeogenesis. Dashed lines are used for the potential mechanism for treating mitochondrial diseases as figure shows: (a) Glycolysis activation: exogenous pyruvate was reduced by LDH to provide NAD+ for glycolysis; (b) PDHC activation: pyruvate inhibits PDK to activate PDHC for generation of acetyl-CoA; (c) eliminates free oxygen radicals by a non-enzymatic reaction.\
G-3-PD, glyceraldehyde 3-phosphate dehydrogenase; LDH, lactate dehydrogenase; MCT, monocarboxylate transporter; MPC, mitochondrial pyruvate carrier; OXPHOS, oxidative phosphorylation; PC, pyruvate carboxylase; PDHC, pyruvate dehydrogenase complex; PDK, pyruvate dehydrogenase kinase; TCA, tricarboxylic acid.](10.1177_2042018820938240-fig1){#fig1-2042018820938240}

In theory, the potential mechanism of pyruvate therapy to improve mitochondrial disease is as follows ([Figure 1](#fig1-2042018820938240){ref-type="fig"}): (a) Glycolysis activation: in the cytosol, exogenous pyruvate is reduced to lactate by LDH to provide NAD+ for the oxidation of glyceraldehyde-3-phosphate in the glycolysis, and then activates glycolysis to protect ATP for sustaining cellular functions, even in the environment of high concentration of lactate or under a high lactate/pyruvate (L/P) ratio^[@bibr18-2042018820938240]^; (b) PDHC activation: in the mitochondria, PDHC is inhibited by pyruvate dehydrogenase kinases (PDK) and activated by pyruvate dehydrogenase phosphatase (PDP). Exogenous pyruvate inhibits PDK to make PDP restore the activity of PDHC, which catalyzes more pyruvate convert to acetyl-CoA for the TCA cycle^[@bibr18-2042018820938240]^; (c) antioxidant activity: in a stoichiometric manner, pyruvate eliminates free oxygen radicals (such as hydrogen peroxide) in hypoxia by a non-enzymatic reaction.^[@bibr19-2042018820938240]^ Furthermore, pyruvate raises intracellular pH by consuming H^+^ under both anoxic and aerobic conditions so as to reduce intracellular acidosis effectively. Additionally, pyruvate consumes an additional H^+^ by PC reaction during gluconeogenesis.^[@bibr19-2042018820938240]^ Studies *in vitro* and *in vivo* have indicated that pyruvate exhibits antioxidant effects and improved glucose metabolism disorders.^[@bibr20-2042018820938240],[@bibr21-2042018820938240]^ A double-blind, placebo-controlled, crossover study concluded that pyruvate ingestion (0.1g/kg) 1 h before workout modified lactate production during exercise.^[@bibr22-2042018820938240]^ In recent years, pyruvate therapy for mitochondrial disease has been reported.^[@bibr23-2042018820938240][@bibr24-2042018820938240]--[@bibr25-2042018820938240]^ The present study integrated clinical studies to evaluate the efficacy and safety of pyruvate therapy and to provide a novel perspective on the clinical treatment of mitochondrial disease.

Methods {#section6-2042018820938240}
=======

This study was registered in PROSPERO (CRD 141196). The study design complies with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).^[@bibr26-2042018820938240],[@bibr27-2042018820938240]^

Search strategy {#section7-2042018820938240}
---------------

Relevant studies were systematically searched in the following four databases: Pubmed, Embase, Cochrane Library, and *ClinicalTrials*, from database inception to 23 April 2019. The search was carried out using both Medical Subject Headings (MeSH) and free text terms. Major search terms included "pyruvate", "mitochondrial disease", "mitochondrial", "Leigh syndrome", and "MELAS syndrome". The following search strategy was used: (pyruvate OR sodium pyruvate OR pyruvate therapy) AND (mitochondrial disease OR mitochondrial OR Leigh syndrome OR MELAS syndrome).

Criteria for studies {#section8-2042018820938240}
--------------------

All observational and experimental studies that assessed the efficacy and safety of pyruvate therapy in mitochondrial diseases were included. No restrictions were placed on the type of research, subtype of disease or publication language. Studies where the full text was not published, such as conference abstracts and letters to the editors were excluded. Moreover, all patients who were genetically, biochemically, and clinically diagnosed with mitochondrial disease, regardless of age and gender, were included.

The inclusion criteria included: (1) study on any design; (2) patients diagnosed genetically, biochemically, and clinically with mitochondrial disease regardless of age and gender; (3) pyruvate therapy in any formula by any administration route; (4) included at least one of the following outcomes before and after pyruvate therapy: biomarkers as plasma lactate level, plasma pyruvate level, L/P ratio, serum concentrations of growth differentiation factor 15 (GDF 15) and fibroblast growth factor 21 (FGF21), and clinical rating scales as Japanese Mitochondrial Disease-Rating Scale (JMDRS),^[@bibr12-2042018820938240]^ Newcastle Mitochondrial Disease Adult Scale (NMDAS),^[@bibr28-2042018820938240]^ or Newcastle Pediatric Mitochondrial Disease Scale (NPMDS).^[@bibr29-2042018820938240]^

Titles and abstracts were screened to exclude initially irrelevant articles. The full texts of the remaining articles were reviewed and assessed by two independent reviewers. Disagreements were discussed by consensus from all authors.

Data extraction and synthesis {#section9-2042018820938240}
-----------------------------

Using a data extraction form, data collection was performed by two reviewers. The data extraction form included the following six categories: (1) study characteristics, such as author, year(s) of publication, country and study design; (2) treatment characteristics, including therapy period, follow-up period, sample size, administration route, and dose; (3) participant characteristics, such as number of participants, mean age/median age, gender ratio, subtype of mitochondrial disease, and baseline data; (4) study quality, namely quality evaluation, and explanation; (5) outcome measures, such as biomarkers (plasma level of lactate, plasma level of pyruvate, L/P ratio, serum GDF 15, and FGF21), clinical rating scales (JMDRS, NMDRS, and other); (6) adverse events reported.

The included studies were not easily comparable because of differences in study design, dosage of treatments, duration of study, and types of participants included. Due to these heterogeneities, a meta-analysis on the identified studies was not performed. Therefore, the data were only presented and described together.

Assessment of quality {#section10-2042018820938240}
---------------------

Case series and case reports were assessed by The Joanna Briggs Institute Critical Appraisal tools.^[@bibr30-2042018820938240]^ Non-randomized controlled studies of interventions were assessed by Risk Of Bias In Non-randomized Studies of Interventions (ROBINS-I).^[@bibr31-2042018820938240]^ Randomized controlled trials were assessed by the Cochrane Risk of Bias tool.^[@bibr32-2042018820938240]^ The studies were scored as low, moderate, or high risk of bias according to each criteria.

Results {#section11-2042018820938240}
=======

Description of studies: results of the search/included studies/excluded studies {#section12-2042018820938240}
-------------------------------------------------------------------------------

A total of 2322 articles were identified following removal of the duplicates. After screening of titles and abstracts, 2300 articles were excluded. The remaining 22 articles were evaluated by full text. A total of 10 studies were irrelevant, 2 articles were reviews and 4 studies were published only as abstracts.^[@bibr25-2042018820938240],[@bibr33-2042018820938240][@bibr34-2042018820938240]--[@bibr35-2042018820938240]^ Overall, one non-randomized study of interventions and 5 case reports were eligible for inclusion and were included in the systematic review, outlined in the PRISMA flow diagram ([Figure 2](#fig2-2042018820938240){ref-type="fig"}).^[@bibr23-2042018820938240],[@bibr24-2042018820938240],[@bibr37-2042018820938240][@bibr38-2042018820938240]--[@bibr39-2042018820938240]^

![The PRISMA flow diagram.\
PRISMA, preferred reporting items for systematic reviews and meta-analyses.](10.1177_2042018820938240-fig2){#fig2-2042018820938240}

The main study characteristics of the included studies are presented in [Table 1](#table1-2042018820938240){ref-type="table"}. There was variability across the results with respect to study design, intervention, and outcome measures. All the studies were from Japan. The total number of patients was 19. Six studies included participants with several types of mitochondrial diseases \[mitochondria, including MELAS, Leigh syndrome (LS), Kearns-Sayre syndrome (KSS), mitochondrial diabetes mellitus, and mitochondrial DNA depletion syndrome\]. No significant difference was noted in terms of drug intervention. The pyruvate therapy used in the selected studies chose sodium pyruvate (dose range = 0.25--0.5 g/kg/day) in different administrations. The duration of pyruvate therapy was variable, ranging from 2 months to 66 months.

###### 

Characteristics of the included studies.

![](10.1177_2042018820938240-table1)

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                         Study design                   Patients   Intervention\       Therapy duration   Inclusion criteria      Outcomes measures                                                                                                                                                                                                                                                            
                                                                                          (sodium pyruvate)                                                                                                                                                                                                                                                                                                                           
  --------------------------------------------- ------------------------------ ---------- ------------------- ------------------ ----------------------- ---------------------------------------------------------------------------------------------------- ---------------------------------------------------------------- ------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------
  Koga *et al*.^[@bibr36-2042018820938240]^     Prospective, single-centre,\   11         16--62              M:F=6:5            A3243G(9)\              Initial dose of 0.25 g/kg/day tid, orally; after 4 weeks, maintenance dose of 0.5 g/kg tid, orally   48 weeks                                                         Mitochondrial diseases^[a](#table-fn1-2042018820938240){ref-type="table-fn"}^ (CM, MELAS, MELA, KSS)   Plasma lactate level, plasma pyruvate level, L/P ratio, serum GDF15 and FGF21, JMDRS, NMDAS
                                                exploratory, clinical study                                                      Large deletions in\                                                                                                                                                                                                                                                                                  
                                                                                                                                 mtDNA(2)                                                                                                                                                                                                                                                                                             

  Fujii *et al*.^[@bibr37-2042018820938240]^    Case report                    4          8--100 months       M:F=2:2            m.8993 T\>G (1)\        0.5 g/kg/day bid, oral or through a feeding tube; maintenance dose of 0.5\~1.0 g/kg/d bid            17--66 months                                                    Mitochondrial diseases^[b](#table-fn2-2042018820938240){ref-type="table-fn"}^ (Leigh syndrome,\        Plasma lactate level, L/P ratio, JMDRS, NPMDS
                                                                                                                                 m.9176 T\>C (1)\                                                                                                                                                                              encephalomyopathy\                                                                                     
                                                                                                                                 not published (1)\                                                                                                                                                                            Myopathic mitochondrial depletion syndrome)                                                            
                                                                                                                                 mtDNA depletion (1)                                                                                                                                                                                                                                                                                  

  Komaki *et al*.^[@bibr23-2042018820938240]^   Case report                    1          11                  F                  not determined (1)      0.5 g/kg/day, orally                                                                                 1 year^[c](#table-fn3-2042018820938240){ref-type="table-fn"}^    Leigh syndrome                                                                                         Plasma lactate level, Plasma pyruvate level, L/P ratio

  Koga *et al*.^[@bibr24-2042018820938240]^     Case report                    1          5                   M                  PDH E1a c.559A\>C (1)   0.5 g/kg/day tid, orally                                                                             3 years^[d](#table-fn4-2042018820938240){ref-type="table-fn"}^   Leigh syndrome                                                                                         Plasma lactate level, Plasma pyruvate level, L/P ratio

  Saito *et al*.^[@bibr38-2042018820938240]^    Case report                    1          1                   F                  mtDNA depletion (1)     0.5 g/kg/day tid, through a nasogastric tube                                                         2 months                                                         mitochondrial DNA depletion syndrome                                                                   Plasma lactate level, L/P ratio, NPMDS

  Inoue *et al*.^[@bibr39-2042018820938240]^    Case report                    1          32                  M                  m.14709T\>C(1)          0.5 g/kg/day tid, orally                                                                             10 months                                                        Mitochondrial diabetes mellitus                                                                        Plasma lactate level, Plasma pyruvate level, L/P ratio, JMDRS
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

There were four subtypes of mitochondrial diseases in this study: 2 CM patients, 4 MELAS patients, 3 MELA patients, 2 KSS patients (with large deletions in mtDNA).

There were four subtypes of mitochondrial diseases in this study: 2 patients with Leigh syndrome, one patient with nonspecific encephalomyopathy associated with complex I and IV combined deficiency and another patient with myopathic mitochondrial DNA depletion syndrome. The common characteristics was OXPHOS disorders.

It is mentioned in the article that the follow-up time is 1 year, which refers to the treatment time through the full text analysis.

It is noted that the patient actually administrated pyruvate sodium for a 3-year period, and the measurement time of outcome was 58 weeks.

CM, cardiomyopathy; FGF21, fibroblast growth factor 21; JMDRS, Japanese Mitochondrial Disease-Rating Scale; KSS, Kearns-Sayre syndrome; L/P lactate/pyruvate; MELA, mitochondrial encephalopathy, and lactic acidosis; MELAS, mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes; mtDNA, mitochondrial DNA; NMDAS, Newcastle Pediatric Mitochondrial Disease Scale; PDH, pyruvate dehydrogenase.

Evaluation of quality of included studies {#section13-2042018820938240}
-----------------------------------------

Due to case series and case reports included, the Joanna Briggs Institute Critical Appraisal tools was used to evaluate the included studies. The overall appraisal of the included trials was shown in [Table 2](#table2-2042018820938240){ref-type="table"}. The study by Koga was included although it has insufficient demographic information and incomplete inclusion of participants.^[@bibr36-2042018820938240]^ There is also lack of detailed method information about identification of the condition of the participants. The five included case reports were all included with some loss of data: Fujii 2014 did not describe clearly the medical history, clinical condition, and diagnostic methods^[@bibr37-2042018820938240]^; Komaki 2010 recorded the intervention procedure clearly but only administration frequency; the time to clinical evaluation was also not reported.^[@bibr23-2042018820938240]^

###### 

The quality checklist for the included studies.

![](10.1177_2042018820938240-table2)

                                                JBI critical appraisal tools - checklist for case reports                                                                                                                                                           
  --------------------------------------------- ----------------------------------------------------------- ----- --------- --------- ----------------------------------------------------- ----------------------------------------------------------- ----- ----- ----------
  Fujii *et al*.^[@bibr37-2042018820938240]^    Yes                                                         No    Unclear   Unclear   Yes                                                   Yes                                                         Yes   Yes   Included
  Komaki *et al*.^[@bibr23-2042018820938240]^   Yes                                                         Yes   Yes       Yes       Yes, only administration frequency was not reported   Yes, but the time to clinical evaluation was not reported   Yes   Yes   Included
  Koga *et al*.^[@bibr24-2042018820938240]^     Yes                                                         Yes   Yes       Yes       Yes                                                   Yes                                                         Yes   Yes   Included
  Saito *et al*.^[@bibr38-2042018820938240]^    Yes                                                         Yes   Yes       Yes       Yes                                                   Yes                                                         Yes   Yes   Included
  Inoue *et al*.^[@bibr39-2042018820938240]^    Yes                                                         Yes   Yes       Yes       Yes                                                   Yes                                                         Yes   Yes   Included

                                              JBI critical appraisal tools - checklist for case series                                                           
  ------------------------------------------- ---------------------------------------------------------- ----- --------- ----- ---- ----- ----- ----- ---- ----- ----------
  Koga *et al*.^[@bibr36-2042018820938240]^   Yes                                                        Yes   Unclear   Yes   No   Yes   Yes   Yes   No   Yes   Included

The answer "Yes", "Unclear" and "No" was marked as 2, 1 and 0 points. The total quality grade was marked: the score of ⩾ 12 as high quality, 12--8 as moderate quality, ⩽8 as low quality.

The answer "Yes", "Unclear" and "No" was marked as 2, 1 and 0 points. The total quality grade was marked: the score of ⩾ 17 as high quality, 17--12 as moderate quality, ⩽12 as low quality.

JBI, Joanna Briggs Institute.

Effects of interventions {#section14-2042018820938240}
------------------------

All the identified studies used more than one kind of outcome to evaluate the efficacy of pyruvate therapy. The most common outcomes of assessment were the plasma lactate levels and L/P ratio, which were used in six studies. Two out of six studies (Koga 2019 and Komaki 2010)^[@bibr23-2042018820938240],[@bibr36-2042018820938240]^ demonstrated a remarkable decrease in plasma lactate levels and L/P ratio. Koga 2012 suggested that pyruvate therapy decreased lactate, pyruvate, and alanine levels,^[@bibr24-2042018820938240]^ although the differences were not statistically significant. However, the other three case reports including six patients who reported no significant improvement with regard to these parameters.^[@bibr37-2042018820938240][@bibr38-2042018820938240]--[@bibr39-2042018820938240]^ Besides, clinical rating scales were evaluated as secondary outcomes in five studies (outlined in [Table 3](#table3-2042018820938240){ref-type="table"}). Furthermore, functional improvements in patients were represented in almost every article, despite the fact that the primary outcomes showed negative results. In the studies by Fujii and Saito,^[@bibr37-2042018820938240],[@bibr38-2042018820938240]^ five patients showed mild improvements in the movement of extremities, at least in the short term. Komaki 2010 reported remarkable improvements in exercise intolerance and cardiac dysfunction so that the patient gained the ability of running.^[@bibr23-2042018820938240]^ The improvement in cardiac function and diabetic parameters was reported in the studies of Koga and Inoue, respectively.^[@bibr24-2042018820938240],[@bibr39-2042018820938240]^ There were too few homogeneous clinical studies to conduct a meta-analysis, so a narrative synthesis only was performed.

###### 

The outcomes of the included studies.

![](10.1177_2042018820938240-table3)

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                         Primary outcomes    Secondary outcomes                                                          Other qualitative outcomes                                                                                                                                                                
  --------------------------------------------- ------------------- --------------------------------------------------------------------------- ---------------------------- ----------------- ------------- -------------------------------------------------------------------- ------------- ------------- ------------- ------------- -----------------------------------------------------------------------------------------------------------------
  Koga *et al*.^36b^                            50.5 ± 12.5 mg/dl   30.4 ± 5.08 mg/dl^[f](#table-fn14-2042018820938240){ref-type="table-fn"}^   1.9 ± 0.5 mg/dl              1.5 ± 0.3 mg/dl   28.1 ± 8.6    20.7 ± 3.5^[c](#table-fn11-2042018820938240){ref-type="table-fn"}^   24.1 ± 19.7   21.0 ± 22.4   38.6 ± 28.7   33.3 ± 30.7   Significant decrease from the baseline values in serum GDF15 level and lactate cerebral ventricular levels

  Fujii *et al*.^37d^                           1.2 mM              0.85 mM                                                                     NA                           NA                19.7          20                                                                   NA            NA            42.3          38.6          Able to roll over and raise the leg 90°

                                                2.8 mM              2.4 mM                                                                      NA                           NA                23.2          23.1                                                                 52            53            34.2          53.7          Able to roll over and full oral feeding

                                                3.9 mM              5.6 mM                                                                      NA                           NA                25            30.5                                                                 NA            NA            44.7          28.3          Able to roll over bilaterally and dysphagia disappeared^[e](#table-fn13-2042018820938240){ref-type="table-fn"}^

                                                2.3 mM              2.5 mM                                                                      NA                           NA                16.9          17.3                                                                 NA            NA            35            64.8          Mild improvement in the movement of extremities^[f](#table-fn14-2042018820938240){ref-type="table-fn"}^

  Komaki *et al*.^[@bibr23-2042018820938240]^   20.5 mg/dl          10.3 mg/dl                                                                  1.13 mg/dl                   0.88 mg/dl        18.1          11.7                                                                 NA            NA            NA            NA            capable of running; improvement in exercise intolerance and cardiac dysfunction

  Koga *et al*.^[@bibr24-2042018820938240]^     9.6 ± 0.54 mM       5.28 ± 1.73 mM                                                              0.69 ± 0.13 mM               0.42 ± 0.13mM     14.5 ± 3.10   12.6 ± 1.52                                                          58            57            NA            NA            significantly decreased level of alanine\
                                                                                                                                                                                                                                                                                                                                          improvement in the electroencephalogram

  Saito *et al*.^[@bibr38-2042018820938240]^    2.3 mM              2.3 mM                                                                      NA                           NA                18            18                                                                   NA            NA            35            31            Able to raise her forearm, lower leg and wrist against gravity

  Inoue *et al*.^[@bibr39-2042018820938240]^    1.86 mM             2.94 mM                                                                     0.12 mM                      0.26 mM           15.4          11.3                                                                 23            26            NA            NA            The improvement of diabetes parameters
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

This scale has four age group classifications: 0--24 months, 2--11 years, and 12--18 years from NPMDS, and an adult age group classification from NMDAS.

In addition, a significant decrease from the baseline values in GDF-15 was reported. The JMDRS overall scores did not change significantly from the baseline values at weeks 48 of pyruvate therapy, although the JMDRS scores decreased significantly from the baseline values at weeks 12 of pyruvate therapy.

Significance between none and pyruvate therapy.

The report in detail monitored four bedridden patients with OXPHOS disorders in their treatment process.

The patient gained the ability to roll over bilaterally and the dysphagia disappeared after 2 months of pyruvate therapy, but a slow regression in motor function was observed over next 10 months.

In the included study, two units were used for lactic acid and pyruvate concentration: mg/dl and mM.

JMDRS, Japanese Mitochondrial Disease-Rating Scale; L/P lactate/pyruvate; NMDAS, Newcastle Pediatric Mitochondrial Disease Scale; NPMDS, Newcastle Pediatric Mitochondrial Disease Scale.

With regard to safety, diarrhea was observed as the most common adverse effect during pyruvate therapy.^[@bibr23-2042018820938240],[@bibr24-2042018820938240],[@bibr36-2042018820938240],[@bibr37-2042018820938240]^ Moreover, nausea and irritation of the stomach shortly were reported in a 48-week, prospective, single-center, exploratory, clinical study.^[@bibr36-2042018820938240]^ It is worth mentioning that no patients experienced adverse events, including diarrhea, in Saito 2012 and Inoue 2016.^[@bibr38-2042018820938240],[@bibr39-2042018820938240]^

Discussion {#section15-2042018820938240}
==========

Due to the rarity and complexity of mitochondrial diseases, clinical studies with pyruvate therapy are very limited. Only six studies were included to investigate the efficacy and safety of pyruvate therapy for mitochondrial diseases. Other than five case reports, the only clinical study was a prospective, single-center, exploratory study, which enrolled 11 Japanese adult patients with mitochondrial disease. This study mainly explored biomarkers and clinical rating scales, which may be applicable to the evaluation of pyruvate therapy. According to the results of this study, plasma lactate levels, plasma pyruvate levels, and L/P ratio were the primary outcomes. The remaining five studies were case reports and, in total, described eight patients with mitochondrial diseases treated with pyruvate therapy. Given the limitations of case report, their results must be interpreted cautiously. It is worth noting that four studies were excluded for the following reasons. Two studies were excluded due to the lack of full text.^[@bibr25-2042018820938240],[@bibr33-2042018820938240]^ Although the case report by Kuroha was complete,^[@bibr34-2042018820938240]^ the paper was written in Japanese and could not be translated because of password restrictions. In the Hirano study,^[@bibr33-2042018820938240]^ 13 participants were enrolled and the majority of the outcomes were consistent with ours. Unfortunately, we failed to contact the authors by email.

The evidence gathered in the present review demonstrates an effective potential of pyruvate therapy in improving outcomes in mitochondrial disease. Three of the studies included indicated that pyruvate could significantly decrease plasma lactic acid levels and L/P ratio, ^[@bibr23-2042018820938240],[@bibr24-2042018820938240],[@bibr36-2042018820938240]^ as manifested in two excluded studies,^[@bibr33-2042018820938240],[@bibr34-2042018820938240]^ with the exception of the Koga study,^[@bibr36-2042018820938240]^ where this decrease was not dramatically different. On the contrary, no change was found in the plasma lactic acid levels and L/P ratio in the other two studies,^[@bibr37-2042018820938240],[@bibr38-2042018820938240]^ and there was even a tendency to increase.^[@bibr39-2042018820938240]^ Although case reports did not demonstrate that pyruvate reduced lactic acid levels significantly, another excluded open study supported the possibility of pyruvate reducing lactic acid and the novel biomarker GDF-15.^[@bibr33-2042018820938240]^ It is worth mentioning that functional improvements were common in both included and excluded studies, especially motor function and cardiac function. The patients involved in functional improvements were newborns or children, which suggested that pyruvate therapy may promote the growth and development of children with mitochondrial disease. Furthermore, pyruvate has indicated some advantages in the treatment of mitochondrial diabetes by improvement of diabetes parameters and endogenous insulin secretion.^[@bibr3-2042018820938240],[@bibr39-2042018820938240]^

According to included study, patients at the early stages of mitochondrial diseases are more likely to improve their symptoms by pyruvate therapy. When patients were at advanced stages, disease development may exceed the efficacy of pyruvate therapy, e.g., patient 4 in the Fujii study.^[@bibr37-2042018820938240]^ This may suggest that pyruvate may be more effective in the early stages than advanced stages. The complex pathogenesis of mitochondrial disease may be an additional factor that leads to the limited efficacy of pyruvate therapy. This type of treatment may be aimed at specific patients, such as those who present with LS and MELAS, which are associated with PDHC deficiency, rather than all patients with mitochondrial disease. According to data on the treatment status of the included studies, three patients with LS were more responsive to sodium pyruvate. Genetic data were extracted from the original literature and summarized, but failed to be analyzed due to the limited sample size and high heterogeneity. Furthermore, whether plasma lactic acid levels and L/P ratio can indicate the efficacy of pyruvate therapy is not fully explained and needs further verification. In recent years, several studies have reported that a novel biomarker named GDF-15 is expected to diagnose and monitor treatment.^[@bibr40-2042018820938240][@bibr41-2042018820938240]--[@bibr42-2042018820938240]^ There was also no significant change in clinical score scales (JMDRS, NMDAS, and NPMDS) as secondary outcomes. Among them, NMDAS and NPMDS could not capture subtle changes of motor function, so improvement in children and severe patients could not be monitored effectively with these scales.^[@bibr23-2042018820938240],[@bibr37-2042018820938240]^ Pyruvate is a physiological metabolite, which exhibits few adverse events and further provides a safety guarantee for further research. As suggested above, the present review has suggested that additional advanced clinical trials with large sample sizes and adaptive study designs are required. One report published recently highlighted that an investigator-initiated clinical trial of sodium pyruvate for MELAS and LS is currently ongoing in Japan.^[@bibr43-2042018820938240]^

At present, the results and conclusions of pyruvate therapy are based on the above studies. Although well-designed case-series and case reports suggested potential efficacy of pyruvate therapy for treatment of mitochondrial disease, the overall certainty of the body of evidence is very low according to the GRADE system. In other words, the causal inferences for pyruvate's effect on mitochondrial disease is still inadequate. Therefore, the following points need to be noted to further study of pyruvate therapy: (1) The improvement of patients may be attributed to the efficacy of pyruvate therapy, but it may also be due to natural motor development, especially functional improvement in children who are in a period of rapid growth. Similarly, the deterioration of condition may suggest that pyruvate therapy is ineffective, but it may be that the rapid deterioration overwhelms its efficacy. Thus, it is very important and necessary to distinguish between the effect of pyruvate therapy and the fluctuating course of the disease. (2) Although the mitochondrial clinical score scale did not manifest subtle changes, improvements in motor function and quality of life were recorded. These artificial records should be carefully considered for subjective and effective factors. (3) Another key issue is whether the statistical significance noted in the various biomarkers corresponds to the effectiveness of pyruvate treatment. For instance, whether plasma lactic acid levels, L/P ratio, and GDF-15 could represent effective treatment of patients remains to be elucidated. (4) According to the existing hypothesis, pyruvate may cause a further increase of lactate levels while improving mitochondrial disease by increasing NAD^+^. The potential mechanisms whereby pyruvate preferably adjusts the balance of lactate and itself have not been fully elucidated. But clearly, metabolism is not always a simple linear process and many metabolites may have multiple potential routes. For example, the role and function of lactate has been redefined and redescribed recently as the Lactate Shuttle Hypothesis.^[@bibr44-2042018820938240],[@bibr45-2042018820938240]^ Thus, more basic research should further explore the function and relationship of lactate and pyruvate in mitochondrial disease.

To our knowledge, this is the first systematic review to examine the contribution of pyruvate therapy for mitochondrial disease. However, there are several limitations. Firstly, the present systematic review had small sample size and specific inconsistencies. Secondly, the types of included studies were case series and anecdotic case reports with patients with complicated conditions, which have too low homogeneity to sum up, so that the evidence quality is low and the analysis of the data is limited. Lastly, some published or unpublished reports may be missing although our search strategy was comprehensive. Based on the above limitations, a reminder is needed to take clinical situations into account when referring to the results of this review.

Conclusion {#section16-2042018820938240}
==========

With no significant adverse effects, pyruvate therapy may be a potential therapeutic candidate for patients with incurable mitochondrial diseases, such as Leigh syndrome. However, recent evidence taken from case series and case reports and theoretical supports of basic research are not sufficient. Despite these challenges, there are many possibilities to understand the mechanism of pyruvate therapy through basic research, and to use global registries and more adaptive trial designs with larger numbers of participants to clarify the efficacy of pyruvate therapy.
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